GLP1R and type 2 diabetes mellitus: Our retrospective cohort study, based on a large age and HbA1c matched nationally-representative T2DM population data source with median follow-up of 3.5 years, showed that treatment with the GLP-1R agonist EBID with or without insulin was associated with reduced rates and risks of major macrovascular events compared with an insulin-treated cohort.